Miller, K., Cortes, J., Hurvitz, S. A., Krop, I. E., Tripathy, D., Verma, S., . . . Yardley, D. A. (2016). HERMIONE: A randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer. BMC Cancer.
Chicago Style CitationMiller, Kathy, et al. "HERMIONE: A Randomized Phase 2 Trial of MM-302 Plus Trastuzumab Versus Chemotherapy of Physician’s Choice Plus Trastuzumab in Patients With Previously Treated, Anthracycline-naïve, HER2-positive, Locally Advanced/metastatic Breast Cancer." BMC Cancer 2016.
Cita MLAMiller, Kathy, et al. "HERMIONE: A Randomized Phase 2 Trial of MM-302 Plus Trastuzumab Versus Chemotherapy of Physician’s Choice Plus Trastuzumab in Patients With Previously Treated, Anthracycline-naïve, HER2-positive, Locally Advanced/metastatic Breast Cancer." BMC Cancer 2016.